ID   LRRK2_HUMAN             Reviewed;        2527 AA.
AC   Q5S007; A6NJU2; Q6ZS50; Q8NCX9;
DT   24-JAN-2006, integrated into UniProtKB/Swiss-Prot.
DT   20-APR-2010, sequence version 2.
DT   10-MAY-2017, entry version 144.
DE   RecName: Full=Leucine-rich repeat serine/threonine-protein kinase 2;
DE            EC=2.7.11.1;
DE   AltName: Full=Dardarin;
GN   Name=LRRK2; Synonyms=PARK8;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND VARIANTS PARK8
RP   VAL-1122; CYS-1441; CYS-1699 AND THR-2020.
RC   TISSUE=Brain;
RX   PubMed=15541309; DOI=10.1016/j.neuron.2004.11.005;
RA   Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M.,
RA   Lincoln S.J., Kachergus J.M., Hulihan M.M., Uitti R.J., Calne D.B.,
RA   Stoessl A.J., Pfeiffer R.F., Patenge N., Carballo Carbajal I.,
RA   Vieregge P., Asmus F., Mueller-Myhsok B., Dickson D.W., Meitinger T.,
RA   Strom T.M., Wszolek Z.K., Gasser T.;
RT   "Mutations in LRRK2 cause autosomal-dominant parkinsonism with
RT   pleomorphic pathology.";
RL   Neuron 44:601-607(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2128-2527.
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   DISEASE.
RX   PubMed=16081470; DOI=10.1093/brain/awh607;
RA   Adams J.R., van Netten H., Schulzer M., Mak E., McKenzie J.,
RA   Strongosky A., Sossi V., Ruth T.J., Lee C.S., Farrer M., Gasser T.,
RA   Uitti R.J., Calne D.B., Wszolek Z.K., Stoessl A.J.;
RT   "PET in LRRK2 mutations: comparison to sporadic Parkinson's disease
RT   and evidence for presymptomatic compensation.";
RL   Brain 128:2777-2785(2005).
RN   [5]
RP   SUBCELLULAR LOCATION, AND CHARACTERIZATION OF VARIANT PARK8 THR-2020.
RX   PubMed=16321986; DOI=10.1093/hmg/ddi439;
RA   Gloeckner C.J., Kinkl N., Schumacher A., Braun R.J., O'Neill E.,
RA   Meitinger T., Kolch W., Prokisch H., Ueffing M.;
RT   "The Parkinson disease causing LRRK2 mutation I2020T is associated
RT   with increased kinase activity.";
RL   Hum. Mol. Genet. 15:223-232(2006).
RN   [6]
RP   DISEASE.
RX   PubMed=16087219; DOI=10.1016/j.mad.2005.06.010;
RA   Toft M., Sando S.B., Melquist S., Ross O.A., White L.R., Aasly J.O.,
RA   Farrer M.J.;
RT   "LRRK2 mutations are not common in Alzheimer's disease.";
RL   Mech. Ageing Dev. 126:1201-1205(2005).
RN   [7]
RP   SUBCELLULAR LOCATION, AND CHARACTERIZATION OF VARIANTS PARK8 CYS-1441
RP   AND SER-2019.
RX   PubMed=16269541; DOI=10.1073/pnas.0507360102;
RA   West A.B., Moore D.J., Biskup S., Bugayenko A., Smith W.W., Ross C.A.,
RA   Dawson V.L., Dawson T.M.;
RT   "Parkinson's disease-associated mutations in leucine-rich repeat
RT   kinase 2 augment kinase activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:16842-16847(2005).
RN   [8]
RP   SUBCELLULAR LOCATION, INTERACTION WITH PRKN, AND POSSIBLE FUNCTION.
RX   PubMed=16352719; DOI=10.1073/pnas.0508052102;
RA   Smith W.W., Pei Z., Jiang H., Moore D.J., Liang Y., West A.B.,
RA   Dawson V.L., Dawson T.M., Ross C.A.;
RT   "Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin and mutant
RT   LRRK2 induces neuronal degeneration.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:18676-18681(2005).
RN   [9]
RP   TISSUE SPECIFICITY.
RX   PubMed=16532471; DOI=10.1002/ana.20808;
RA   Galter D., Westerlund M., Carmine A., Lindqvist E., Sydow O.,
RA   Olson L.;
RT   "LRRK2 expression linked to dopamine-innervated areas.";
RL   Ann. Neurol. 59:714-719(2006).
RN   [10]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=17120249; DOI=10.1002/ana.21019;
RA   Biskup S., Moore D.J., Celsi F., Higashi S., West A.B., Andrabi S.A.,
RA   Kurkinen K., Yu S.W., Savitt J.M., Waldvogel H.J., Faull R.L.,
RA   Emson P.C., Torp R., Ottersen O.P., Dawson T.M., Dawson V.L.;
RT   "Localization of LRRK2 to membranous and vesicular structures in
RT   mammalian brain.";
RL   Ann. Neurol. 60:557-569(2006).
RN   [11]
RP   FUNCTION, CHARACTERIZATION OF VARIANTS PARK8 GLY-1441; CYS-1699;
RP   SER-2019 AND THR-2020, AND VARIANT MET-1906.
RX   PubMed=17114044; DOI=10.1016/j.neuron.2006.10.008;
RA   MacLeod D., Dowman J., Hammond R., Leete T., Inoue K., Abeliovich A.;
RT   "The familial Parkinsonism gene LRRK2 regulates neurite process
RT   morphology.";
RL   Neuron 52:587-593(2006).
RN   [12]
RP   FUNCTION.
RX   PubMed=20949042; DOI=10.1371/journal.pone.0013191;
RA   Zach S., Felk S., Gillardon F.;
RT   "Signal transduction protein array analysis links LRRK2 to Ste20
RT   kinases and PKC zeta that modulate neuronal plasticity.";
RL   PLoS ONE 5:E13191-E13191(2010).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH PRDX3, AND
RP   CHARACTERIZATION OF VARIANT PARK8 SER-2019.
RX   PubMed=21850687; DOI=10.1002/humu.21582;
RA   Angeles D.C., Gan B.H., Onstead L., Zhao Y., Lim K.L., Dachsel J.,
RA   Melrose H., Farrer M., Wszolek Z.K., Dickson D.W., Tan E.K.;
RT   "Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3
RT   exacerbating oxidative stress-induced neuronal death.";
RL   Hum. Mutat. 32:1390-1397(2011).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH TPCN2.
RX   PubMed=22012985; DOI=10.1093/hmg/ddr481;
RA   Gomez-Suaga P., Luzon-Toro B., Churamani D., Zhang L., Bloor-Young D.,
RA   Patel S., Woodman P.G., Churchill G.C., Hilfiker S.;
RT   "Leucine-rich repeat kinase 2 regulates autophagy through a calcium-
RT   dependent pathway involving NAADP.";
RL   Hum. Mol. Genet. 21:511-525(2012).
RN   [15]
RP   SUBUNIT, AND AUTOPHOSPHORYLATION.
RX   PubMed=22952686; DOI=10.1371/journal.pone.0043472;
RA   Civiero L., Vancraenenbroeck R., Belluzzi E., Beilina A.,
RA   Lobbestael E., Reyniers L., Gao F., Micetic I., De Maeyer M.,
RA   Bubacco L., Baekelandt V., Cookson M.R., Greggio E., Taymans J.M.;
RT   "Biochemical characterization of highly purified leucine-rich repeat
RT   kinases 1 and 2 demonstrates formation of homodimers.";
RL   PLoS ONE 7:E43472-E43472(2012).
RN   [16]
RP   FUNCTION IN RETROGRADE TRANSPORT, INTERACTION WITH RAB29 AND VPS35,
RP   SUBCELLULAR LOCATION, CHARACTERIZATION OF VARIANT PARK8 SER-2019, AND
RP   CHARACTERIZATION OF VARIANT MET-1906.
RX   PubMed=23395371; DOI=10.1016/j.neuron.2012.11.033;
RA   MacLeod D.A., Rhinn H., Kuwahara T., Zolin A., Di Paolo G.,
RA   McCabe B.D., MacCabe B.D., Marder K.S., Honig L.S., Clark L.N.,
RA   Small S.A., Abeliovich A.;
RT   "RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting
RT   and Parkinson's disease risk.";
RL   Neuron 77:425-439(2013).
RN   [17]
RP   WD REPEATS.
RX   PubMed=23776530; DOI=10.1371/journal.pone.0065705;
RA   Wang Y., Jiang F., Zhuo Z., Wu X.H., Wu Y.D.;
RT   "A method for WD40 repeat detection and secondary structure
RT   prediction.";
RL   PLoS ONE 8:E65705-E65705(2013).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [19]
RP   FUNCTION, SUBCELLULAR LOCATION, ELECTRON MICROSCOPY, WD REPEATS, AND
RP   CHARACTERIZATION OF VARIANT ARG-2385.
RX   PubMed=24687852; DOI=10.1128/MCB.00914-13;
RA   Piccoli G., Onofri F., Cirnaru M.D., Kaiser C.J., Jagtap P.,
RA   Kastenmuller A., Pischedda F., Marte A., von Zweydorf F., Vogt A.,
RA   Giesert F., Pan L., Antonucci F., Kiel C., Zhang M., Weinkauf S.,
RA   Sattler M., Sala C., Matteoli M., Ueffing M., Gloeckner C.J.;
RT   "Leucine-rich repeat kinase 2 binds to neuronal vesicles through
RT   protein interactions mediated by its C-terminal WD40 domain.";
RL   Mol. Cell. Biol. 34:2147-2161(2014).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 1333-1516 IN COMPLEX WITH
RP   GDP, FUNCTION, GTPASE ACTIVITY, SUBUNIT, DOMAIN ROC, AND MUTAGENESIS
RP   OF THR-1343 AND ARG-1398.
RX   PubMed=18230735; DOI=10.1073/pnas.0709098105;
RA   Deng J., Lewis P.A., Greggio E., Sluch E., Beilina A., Cookson M.R.;
RT   "Structure of the ROC domain from the Parkinson's disease-associated
RT   leucine-rich repeat kinase 2 reveals a dimeric GTPase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:1499-1504(2008).
RN   [21]
RP   VARIANTS PARK8 GLY-1441 AND CYS-1699, AND TISSUE SPECIFICITY.
RX   PubMed=15541308; DOI=10.1016/j.neuron.2004.10.023;
RA   Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J.,
RA   van der Brug M., Lopez de Munain A., Aparicio S., Gil A.M., Khan N.L.,
RA   Johnson J., Martinez J.R., Nicholl D., Carrera I.M., Pena A.S.,
RA   de Silva R., Lees A.J., Marti-Masso J.F., Perez-Tur J., Wood N.W.,
RA   Singleton A.B.;
RT   "Cloning of the gene containing mutations that cause PARK8-linked
RT   Parkinson's disease.";
RL   Neuron 44:595-600(2004).
RN   [22]
RP   VARIANT PARK8 SER-2019.
RX   PubMed=15726496; DOI=10.1086/429256;
RA   Kachergus J.M., Mata I.F., Hulihan M., Taylor J.P., Lincoln S.,
RA   Aasly J.O., Gibson J.M., Ross O.A., Lynch T., Wiley J., Payami H.,
RA   Nutt J., Maraganore D.M., Czyzewski K., Styczynska M., Wszolek Z.K.,
RA   Farrer M.J., Toft M.;
RT   "Identification of a novel LRRK2 mutation linked to autosomal dominant
RT   parkinsonism: evidence of a common founder across European
RT   populations.";
RL   Am. J. Hum. Genet. 76:672-680(2005).
RN   [23]
RP   VARIANT PARK8 SER-2019.
RX   PubMed=15732108; DOI=10.1002/ana.20401;
RA   Hernandez D.G., Paisan-Ruiz C., McInerney-Leo A., Jain S.,
RA   Meyer-Lindenberg A., Evans E.W., Berman K.F., Johnson J., Auburger G.,
RA   Schaeffer A.A., Lopez G.J., Nussbaum R.L., Singleton A.B.;
RT   "Clinical and positron emission tomography of Parkinson's disease
RT   caused by LRRK2.";
RL   Ann. Neurol. 57:453-456(2005).
RN   [24]
RP   VARIANT PARK8/PD SER-2019.
RX   PubMed=15852371; DOI=10.1002/ana.20456;
RA   Aasly J.O., Toft M., Fernandez-Mata I., Kachergus J.M., Hulihan M.,
RA   White L.R., Farrer M.J.;
RT   "Clinical features of LRRK2-associated Parkinson's disease in central
RT   Norway.";
RL   Ann. Neurol. 57:762-765(2005).
RN   [25]
RP   VARIANT PARK8 SER-2019.
RX   PubMed=16240353; DOI=10.1002/ana.20636;
RG   French Parkinson's disease genetics study group;
RA   Lesage S., Ibanez P., Lohmann E., Pollak P., Tison F., Tazir M.,
RA   Leutenegger A.-L., Guimaraes J., Bonnet A.-M., Agid Y., Duerr A.,
RA   Brice A.;
RT   "G2019S LRRK2 mutation in French and North African families with
RT   Parkinson's disease.";
RL   Ann. Neurol. 58:784-787(2005).
RN   [26]
RP   VARIANT PARK8 THR-2020.
RX   PubMed=15880653; DOI=10.1002/ana.20484;
RA   Funayama M., Hasegawa K., Ohta E., Kawashima N., Komiyama M., Kowa H.,
RA   Tsuji S., Obata F.;
RT   "An LRRK2 mutation as a cause for the parkinsonism in the original
RT   PARK8 family.";
RL   Ann. Neurol. 57:918-921(2005).
RN   [27]
RP   VARIANT PARK8 SER-2019.
RX   PubMed=15929036; DOI=10.1002/ana.20510;
RA   Deng H., Le W., Guo Y., Hunter C.B., Xie W., Jankovic J.;
RT   "Genetic and clinical identification of Parkinson's disease patients
RT   with LRRK2 G2019S mutation.";
RL   Ann. Neurol. 57:933-934(2005).
RN   [28]
RP   VARIANTS PARK8 MET-793; ARG-930; CYS-1096 THR-1228; SER-2019 AND
RP   THR-2020, AND VARIANT LYS-551.
RX   PubMed=16251215; DOI=10.1093/brain/awh666;
RA   Berg D., Schweitzer K., Leitner P., Zimprich A., Lichtner P.,
RA   Belcredi P., Bruessel T., Schulte C., Maass S., Naegele T.;
RT   "Type and frequency of mutations in the LRRK2 gene in familial and
RT   sporadic Parkinson's disease.";
RL   Brain 128:3000-3011(2005).
RN   [29]
RP   VARIANTS PARK8 CYS-1699; HIS-1941; SER-2019 AND ILE-2356.
RX   PubMed=16272164; DOI=10.1093/brain/awh667;
RA   Khan N.L., Jain S., Lynch J.M., Pavese N., Abou-Sleiman P.M.,
RA   Holton J.L., Healy D.G., Gilks W.P., Sweeney M.G., Ganguly M.,
RA   Gibbons V., Gandhi S., Vaughan J., Eunson L.H., Katzenschlager R.,
RA   Gayton J., Lennox G., Revesz T., Nicholl D., Bhatia K.P., Quinn N.,
RA   Brooks D., Lees A.J., Davis M.B., Piccini P., Singleton A.B.,
RA   Wood N.W.;
RT   "Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial
RT   Parkinson's disease: clinical, pathological, olfactory and functional
RT   imaging and genetic data.";
RL   Brain 128:2786-2796(2005).
RN   [30]
RP   VARIANTS PARK8 VAL-1371; CYS-1441 AND SER-2019.
RX   PubMed=16333314; DOI=10.1038/sj.ejhg.5201539;
RA   Di Fonzo A., Tassorelli C., De Mari M., Chien H.F., Ferreira J.,
RA   Rohe C.F., Riboldazzi G., Antonini A., Albani G., Mauro A.,
RA   Marconi R., Abbruzzese G., Lopiano L., Fincati E., Guidi M.,
RA   Marini P., Stocchi F., Onofrj M., Toni V., Tinazzi M., Fabbrini G.,
RA   Lamberti P., Vanacore N., Meco G., Leitner P., Uitti R.J.,
RA   Wszolek Z.K., Gasser T., Simons E.J., Breedveld G.J., Goldwurm S.,
RA   Pezzoli G., Sampaio C., Barbosa E., Martignoni E., Oostra B.A.,
RA   Bonifati V.;
RT   "Comprehensive analysis of the LRRK2 gene in sixty families with
RT   Parkinson's disease.";
RL   Eur. J. Hum. Genet. 14:322-331(2006).
RN   [31]
RP   VARIANT PARK8 SER-2019.
RX   PubMed=16272257; DOI=10.1136/jmg.2005.035568;
RA   Goldwurm S., Di Fonzo A., Simons E.J., Rohe C.F., Zini M., Canesi M.,
RA   Tesei S., Zecchinelli A., Antonini A., Mariani C., Meucci N.,
RA   Sacilotto G., Sironi F., Salani G., Ferreira J., Chien H.F.,
RA   Fabrizio E., Vanacore N., Dalla Libera A., Stocchi F., Diroma C.,
RA   Lamberti P., Sampaio C., Meco G., Barbosa E., Bertoli-Avella A.M.,
RA   Breedveld G.J., Oostra B.A., Pezzoli G., Bonifati V.;
RT   "The G6055A (G2019S) mutation in LRRK2 is frequent in both early and
RT   late onset Parkinson's disease and originates from a common
RT   ancestor.";
RL   J. Med. Genet. 42:E65-E65(2005).
RN   [32]
RP   VARIANT PARK8 SER-2019.
RX   PubMed=15680455; DOI=10.1016/S0140-6736(05)70235-X;
RG   The Parkinson study group-PROGENI investigators;
RA   Nichols W.C., Pankratz N., Hernandez D., Paisan-Ruiz C., Jain S.,
RA   Halter C.A., Michaels V.E., Reed T., Rudolph A., Shults C.W.,
RA   Singleton A., Foroud T.;
RT   "Genetic screening for a single common LRRK2 mutation in familial
RT   Parkinson's disease.";
RL   Lancet 365:410-412(2005).
RN   [33]
RP   VARIANT PARK8 SER-2019.
RX   PubMed=15680456; DOI=10.1016/S0140-6736(05)70236-1;
RG   The Italian Parkinson genetics network;
RA   Di Fonzo A., Rohe C.F., Ferreira J., Chien H.F., Vacca L., Stocchi F.,
RA   Guedes L., Fabrizio E., Manfredi M., Vanacore N., Goldwurm S.,
RA   Breedveld G.J., Sampaio C., Meco G., Barbosa E., Oostra B.A.,
RA   Bonifati V.;
RT   "A frequent LRRK2 gene mutation associated with autosomal dominant
RT   Parkinson's disease.";
RL   Lancet 365:412-415(2005).
RN   [34]
RP   VARIANT PARK8 SER-2019.
RX   PubMed=15680457; DOI=10.1016/S0140-6736(05)70237-3;
RA   Gilks W.P., Abou-Sleiman P.M., Gandhi S., Jain S., Singleton A.,
RA   Lees A.J., Shaw K., Bhatia K.P., Bonifati V., Quinn N.P., Lynch J.M.,
RA   Healy D.G., Holton J.L., Revesz T., Wood N.W.;
RT   "A common LRRK2 mutation in idiopathic Parkinson's disease.";
RL   Lancet 365:415-416(2005).
RN   [35]
RP   VARIANT PARK8 SER-2019.
RX   PubMed=15811454; DOI=10.1016/S0140-6736(05)74809-1;
RA   Toft M., Mata I.F., Kachergus J.M., Ross O.A., Farrer M.J.;
RT   "LRRK2 mutations and Parkinsonism.";
RL   Lancet 365:1229-1230(2005).
RN   [36]
RP   VARIANT SER-2019.
RX   PubMed=16001413; DOI=10.1002/mds.20618;
RA   Kay D.M., Kramer P., Higgins D.S., Zabetian C.P., Payami H.;
RT   "Escaping Parkinson's disease: a neurologically healthy octogenarian
RT   with the LRRK2 G2019S mutation.";
RL   Mov. Disord. 20:1077-1078(2005).
RN   [37]
RP   VARIANT PARK8 SER-2019.
RX   PubMed=16250030; DOI=10.1002/mds.20751;
RA   Kay D.M., Zabetian C.P., Factor S.A., Nutt J.G., Samii A.,
RA   Griffith A., Bird T.D., Kramer P., Higgins D.S., Payami H.;
RT   "Parkinson's disease and LRRK2: frequency of a common mutation in U.S.
RT   movement disorder clinics.";
RL   Mov. Disord. 21:519-523(2006).
RN   [38]
RP   VARIANTS PARK8 CYS-1441; GLY-1441; HIS-1441; GLN-1514; SER-1542;
RP   GLU-1598; CYS-1699; THR-1869; THR-2012; SER-2019; THR-2020 AND
RP   ARG-2385, AND VARIANTS PRO-119; LYS-551; VAL-723; MET-793; VAL-1122;
RP   ALA-1262; HIS-1398; PRO-1628; THR-1646; THR-1647; ASP-2081; LEU-2119;
RP   ILE-2261 AND THR-2397.
RX   PubMed=16172858; DOI=10.1007/s10048-005-0005-1;
RA   Mata I.F., Kachergus J.M., Taylor J.P., Lincoln S., Aasly J.,
RA   Lynch T., Hulihan M.M., Cobb S.A., Wu R.-M., Lu C.-S., Lahoz C.,
RA   Wszolek Z.K., Farrer M.J.;
RT   "Lrrk2 pathogenic substitutions in Parkinson's disease.";
RL   Neurogenetics 6:171-177(2005).
RN   [39]
RP   VARIANTS PARK8 VAL-1371 AND SER-2019, AND VARIANTS HIS-1398 AND
RP   THR-2397.
RX   PubMed=16157901; DOI=10.1212/01.WNL.0000167552.79769.b3;
RA   Paisan-Ruiz C., Lang A.E., Kawarai T., Sato C., Salehi-Rad S.,
RA   Fisman G.K., Al-Khairallah T., St George-Hyslop P.H., Singleton A.,
RA   Rogaeva E.;
RT   "LRRK2 gene in Parkinson disease: mutation analysis and case control
RT   association study.";
RL   Neurology 65:696-700(2005).
RN   [40]
RP   VARIANT PARK8 GLN-1067.
RX   PubMed=16247070; DOI=10.1212/01.wnl.0000180517.70572.37;
RA   Skipper L., Shen H., Chua E., Bonnard C., Kolatkar P., Tan L.C.S.,
RA   Jamora R.D., Puvan K., Puong K.Y., Zhao Y., Pavanni R., Wong M.C.,
RA   Yuen Y., Farrer M., Liu J.J., Tan E.K.;
RT   "Analysis of LRRK2 functional domains in nondominant Parkinson
RT   disease.";
RL   Neurology 65:1319-1321(2005).
RN   [41]
RP   VARIANTS PARK8 MET-793; THR-1869 AND SER-2019.
RX   PubMed=16157908; DOI=10.1212/01.WNL.0000169023.51764.b0;
RA   Farrer M., Stone J., Mata I.F., Lincoln S., Kachergus J., Hulihan M.,
RA   Strain K.J., Maraganore D.M.;
RT   "LRRK2 mutations in Parkinson disease.";
RL   Neurology 65:738-740(2005).
RN   [42]
RP   VARIANTS PARK8 CYS-1441; HIS-1441 AND SER-2019.
RX   PubMed=16157909; DOI=10.1212/01.WNL.0000172630.22804.73;
RA   Zabetian C.P., Samii A., Mosley A.D., Roberts J.W., Leis B.C.,
RA   Yearout D., Raskind W.H., Griffith A.;
RT   "A clinic-based study of the LRRK2 gene in Parkinson disease yields
RT   new mutations.";
RL   Neurology 65:741-744(2005).
RN   [43]
RP   VARIANT PARK8 GLY-1441.
RX   PubMed=15925109; DOI=10.1016/j.neulet.2005.03.033;
RA   Mata I.F., Taylor J.P., Kachergus J., Hulihan M., Huerta C., Lahoz C.,
RA   Blazquez M., Guisasola L.M., Salvador C., Ribacoba R., Martinez C.,
RA   Farrer M., Alvarez V.;
RT   "LRRK2 R1441G in Spanish patients with Parkinson's disease.";
RL   Neurosci. Lett. 382:309-311(2005).
RN   [44]
RP   VARIANT PARK8 SER-2019.
RX   PubMed=16298482; DOI=10.1016/j.neulet.2005.10.083;
RA   Infante J., Rodriguez E., Combarros O., Mateo I., Fontalba A.,
RA   Pascual J., Oterino A., Polo J.M., Leno C., Berciano J.;
RT   "LRRK2 G2019S is a common mutation in Spanish patients with late-onset
RT   Parkinson's disease.";
RL   Neurosci. Lett. 395:224-226(2006).
RN   [45]
RP   VARIANT PARK8 SER-2019.
RX   PubMed=16102999; DOI=10.1016/j.parkreldis.2005.05.004;
RA   Gosal D., Ross O.A., Wiley J., Irvine G.B., Johnston J.A., Toft M.,
RA   Mata I.F., Kachergus J., Hulihan M., Taylor J.P., Lincoln S.J.,
RA   Farrer M.J., Lynch T., Mark Gibson J.;
RT   "Clinical traits of LRRK2-associated Parkinson's disease in Ireland: a
RT   link between familial and idiopathic PD.";
RL   Parkinsonism Relat. Disord. 11:349-352(2005).
RN   [46]
RP   VARIANTS PARK8 CYS-1441; GLY-1441 AND SER-2019.
RX   PubMed=16533964; DOI=10.1001/archneur.63.3.377;
RA   Gaig C., Ezquerra M., Marti M.J., Munoz E., Valldeoriola F.,
RA   Tolosa E.;
RT   "LRRK2 mutations in Spanish patients with Parkinson disease:
RT   frequency, clinical features, and incomplete penetrance.";
RL   Arch. Neurol. 63:377-382(2006).
RN   [47]
RP   CHARACTERIZATION OF VARIANT ARG-2385, AND ASSOCIATION WITH PARKINSON
RP   DISEASE.
RX   PubMed=17019612; DOI=10.1007/s00439-006-0268-0;
RA   Tan E.K., Zhao Y., Skipper L., Tan M.G., Di Fonzo A., Sun L.,
RA   Fook-Chong S., Tang S., Chua E., Yuen Y., Tan L., Pavanni R.,
RA   Wong M.C., Kolatkar P., Lu C.S., Bonifati V., Liu J.J.;
RT   "The LRRK2 Gly2385Arg variant is associated with Parkinson's disease:
RT   genetic and functional evidence.";
RL   Hum. Genet. 120:857-863(2007).
RN   [48]
RP   VARIANTS [LARGE SCALE ANALYSIS] PRO-119; VAL-419; LYS-551; VAL-723;
RP   HIS-1398; GLN-1514; SER-1542; GLN-1550 AND PRO-1723.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [49]
RP   VARIANTS PARK8 VAL-712; LEU-1728; HIS-1728; SER-2019; MET-2141;
RP   HIS-2143 AND HIS-2466, AND VARIANTS SER-228; VAL-716; GLU-871;
RP   PHE-1870 AND LYS-2395.
RX   PubMed=18213618; DOI=10.1002/humu.20668;
RA   Paisan-Ruiz C., Nath P., Washecka N., Gibbs J.R., Singleton A.B.;
RT   "Comprehensive analysis of LRRK2 in publicly available Parkinson's
RT   disease cases and neurologically normal controls.";
RL   Hum. Mutat. 29:485-490(2008).
RN   [50]
RP   VARIANT ILE-1359.
RX   PubMed=21248752; DOI=10.1038/nature09639;
RA   Varela I., Tarpey P., Raine K., Huang D., Ong C.K., Stephens P.,
RA   Davies H., Jones D., Lin M.L., Teague J., Bignell G., Butler A.,
RA   Cho J., Dalgliesh G.L., Galappaththige D., Greenman C., Hardy C.,
RA   Jia M., Latimer C., Lau K.W., Marshall J., McLaren S., Menzies A.,
RA   Mudie L., Stebbings L., Largaespada D.A., Wessels L.F.A., Richard S.,
RA   Kahnoski R.J., Anema J., Tuveson D.A., Perez-Mancera P.A.,
RA   Mustonen V., Fischer A., Adams D.J., Rust A., Chan-On W., Subimerb C.,
RA   Dykema K., Furge K., Campbell P.J., Teh B.T., Stratton M.R.,
RA   Futreal P.A.;
RT   "Exome sequencing identifies frequent mutation of the SWI/SNF complex
RT   gene PBRM1 in renal carcinoma.";
RL   Nature 469:539-542(2011).
RN   [51]
RP   ASSOCIATION OF VARIANTS PRO-1628 AND ARG-2385 WITH PARKINSON DISEASE.
RX   PubMed=21641266; DOI=10.1016/j.parkreldis.2010.11.008;
RA   Bardien S., Lesage S., Brice A., Carr J.;
RT   "Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2)
RT   associated Parkinson's disease.";
RL   Parkinsonism Relat. Disord. 17:501-508(2011).
RN   [52]
RP   VARIANTS LYS-551; VAL-723; HIS-1398; GLN-1514; SER-1542; PRO-1628;
RP   THR-1646; THR-1647; ASP-2081 AND THR-2397.
RX   PubMed=22415848; DOI=10.1002/humu.22075;
RA   Rubio J.P., Topp S., Warren L., St Jean P.L., Wegmann D., Kessner D.,
RA   Novembre J., Shen J., Fraser D., Aponte J., Nangle K., Cardon L.R.,
RA   Ehm M.G., Chissoe S.L., Whittaker J.C., Nelson M.R., Mooser V.E.;
RT   "Deep sequencing of the LRRK2 gene in 14,002 individuals reveals
RT   evidence of purifying selection and independent origin of the
RT   p.Arg1628Pro mutation in Europe.";
RL   Hum. Mutat. 33:1087-1098(2012).
RN   [53]
RP   VARIANT PARK8 SER-2019.
RX   PubMed=22956510; DOI=10.1002/mds.25132;
RA   Kilarski L.L., Pearson J.P., Newsway V., Majounie E., Knipe M.D.,
RA   Misbahuddin A., Chinnery P.F., Burn D.J., Clarke C.E., Marion M.H.,
RA   Lewthwaite A.J., Nicholl D.J., Wood N.W., Morrison K.E.,
RA   Williams-Gray C.H., Evans J.R., Sawcer S.J., Barker R.A.,
RA   Wickremaratchi M.M., Ben-Shlomo Y., Williams N.M., Morris H.R.;
RT   "Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7
RT   (DJ-1) and LRRK2 in early-onset Parkinson's disease.";
RL   Mov. Disord. 27:1522-1529(2012).
CC   -!- FUNCTION: Positively regulates autophagy through a calcium-
CC       dependent activation of the CaMKK/AMPK signaling pathway. The
CC       process involves activation of nicotinic acid adenine dinucleotide
CC       phosphate (NAADP) receptors, increase in lysosomal pH, and calcium
CC       release from lysosomes. Together with RAB29, plays a role in the
CC       retrograde trafficking pathway for recycling proteins, such as
CC       mannose 6 phosphate receptor (M6PR), between lysosomes and the
CC       Golgi apparatus in a retromer-dependent manner. Regulates neuronal
CC       process morphology in the intact central nervous system (CNS).
CC       Plays a role in synaptic vesicle trafficking. Phosphorylates
CC       PRDX3. Has GTPase activity. May play a role in the phosphorylation
CC       of proteins central to Parkinson disease.
CC       {ECO:0000269|PubMed:17114044, ECO:0000269|PubMed:18230735,
CC       ECO:0000269|PubMed:20949042, ECO:0000269|PubMed:21850687,
CC       ECO:0000269|PubMed:22012985, ECO:0000269|PubMed:23395371,
CC       ECO:0000269|PubMed:24687852}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- SUBUNIT: Homodimer. Interacts with PRKN, PRDX3, RAB29, TPCN2 and
CC       VPS35. {ECO:0000269|PubMed:16352719, ECO:0000269|PubMed:18230735,
CC       ECO:0000269|PubMed:21850687, ECO:0000269|PubMed:22012985,
CC       ECO:0000269|PubMed:22952686, ECO:0000269|PubMed:23395371}.
CC   -!- INTERACTION:
CC       Self; NbExp=66; IntAct=EBI-5323863, EBI-5323863;
CC       Q9UKV8:AGO2; NbExp=3; IntAct=EBI-5323863, EBI-528269;
CC       P31749:AKT1; NbExp=6; IntAct=EBI-5323863, EBI-296087;
CC       Q8N6T3-2:ARFGAP1; NbExp=6; IntAct=EBI-5323863, EBI-6288865;
CC       Q62848:Arfgap1 (xeno); NbExp=7; IntAct=EBI-5323863, EBI-4398879;
CC       Q14155:ARHGEF7; NbExp=7; IntAct=EBI-5323863, EBI-717515;
CC       O95816:BAG2; NbExp=2; IntAct=EBI-5323863, EBI-355275;
CC       O95817:BAG3; NbExp=2; IntAct=EBI-5323863, EBI-747185;
CC       Q9UL15:BAG5; NbExp=12; IntAct=EBI-5323863, EBI-356517;
CC       P10415-1:BCL2; NbExp=2; IntAct=EBI-5323863, EBI-4370304;
CC       Q16543:CDC37; NbExp=7; IntAct=EBI-5323863, EBI-295634;
CC       P60953:CDC42; NbExp=3; IntAct=EBI-5323863, EBI-81752;
CC       P05060:CHGB; NbExp=2; IntAct=EBI-5323863, EBI-712619;
CC       P30275:Ckmt1 (xeno); NbExp=2; IntAct=EBI-5323863, EBI-773103;
CC       P48729-1:CSNK1A1; NbExp=2; IntAct=EBI-5323863, EBI-10106282;
CC       P53355:DAPK1; NbExp=2; IntAct=EBI-5323863, EBI-358616;
CC       Q05193:DNM1; NbExp=4; IntAct=EBI-5323863, EBI-713135;
CC       P39053:Dnm1 (xeno); NbExp=3; IntAct=EBI-5323863, EBI-397785;
CC       O00429:DNM1L; NbExp=11; IntAct=EBI-5323863, EBI-724571;
CC       O00429-3:DNM1L; NbExp=2; IntAct=EBI-5323863, EBI-6896746;
CC       O14640-2:DVL1; NbExp=7; IntAct=EBI-5323863, EBI-6504027;
CC       O14641:DVL2; NbExp=3; IntAct=EBI-5323863, EBI-740850;
CC       Q92997:DVL3; NbExp=4; IntAct=EBI-5323863, EBI-739789;
CC       P30084:ECHS1; NbExp=2; IntAct=EBI-5323863, EBI-719602;
CC       Q13158:FADD; NbExp=4; IntAct=EBI-5323863, EBI-494804;
CC       O14976:GAK; NbExp=10; IntAct=EBI-5323863, EBI-714707;
CC       P49841:GSK3B; NbExp=7; IntAct=EBI-5323863, EBI-373586;
CC       P11142:HSPA8; NbExp=5; IntAct=EBI-5323863, EBI-351896;
CC       P07195:LDHB; NbExp=2; IntAct=EBI-5323863, EBI-358748;
CC       O75581:LRP6; NbExp=4; IntAct=EBI-5323863, EBI-910915;
CC       Q38SD2:LRRK1; NbExp=5; IntAct=EBI-5323863, EBI-1050422;
CC       P46821:MAP1B; NbExp=5; IntAct=EBI-5323863, EBI-9517186;
CC       P46734:MAP2K3; NbExp=5; IntAct=EBI-5323863, EBI-602462;
CC       P52564:MAP2K6; NbExp=4; IntAct=EBI-5323863, EBI-448135;
CC       O14733:MAP2K7; NbExp=3; IntAct=EBI-5323863, EBI-492605;
CC       P10636-2:MAPT; NbExp=3; IntAct=EBI-5323863, EBI-7796412;
CC       P10636-8:MAPT; NbExp=9; IntAct=EBI-5323863, EBI-366233;
CC       P42679:MATK; NbExp=2; IntAct=EBI-5323863, EBI-751664;
CC       P02687:MBP (xeno); NbExp=3; IntAct=EBI-5323863, EBI-908215;
CC       Q811U4:Mfn1 (xeno); NbExp=3; IntAct=EBI-5323863, EBI-9029118;
CC       O95140:MFN2; NbExp=3; IntAct=EBI-5323863, EBI-3324756;
CC       P26038:MSN; NbExp=17; IntAct=EBI-5323863, EBI-528768;
CC       Q96PY6:NEK1; NbExp=2; IntAct=EBI-5323863, EBI-373615;
CC       Q13469:NFATC2; NbExp=3; IntAct=EBI-5323863, EBI-716258;
CC       Q8WUM0:NUP133; NbExp=2; IntAct=EBI-5323863, EBI-295695;
CC       O60313:OPA1; NbExp=3; IntAct=EBI-5323863, EBI-1054131;
CC       Q9NQU5:PAK6; NbExp=2; IntAct=EBI-5323863, EBI-1053685;
CC       O60260:PARK2; NbExp=3; IntAct=EBI-5323863, EBI-716346;
CC       P00634:phoA (xeno); NbExp=2; IntAct=EBI-5323863, EBI-552958;
CC       P62136:PPP1CA; NbExp=6; IntAct=EBI-5323863, EBI-357253;
CC       P30048:PRDX3; NbExp=12; IntAct=EBI-5323863, EBI-748336;
CC       P17612:PRKACA; NbExp=6; IntAct=EBI-5323863, EBI-476586;
CC       P12369:Prkar2b (xeno); NbExp=3; IntAct=EBI-5323863, EBI-6096160;
CC       P61026:RAB10; NbExp=5; IntAct=EBI-5323863, EBI-726075;
CC       Q6IQ22:RAB12; NbExp=2; IntAct=EBI-5323863, EBI-4289591;
CC       Q9H0U4:RAB1B; NbExp=3; IntAct=EBI-5323863, EBI-1045214;
CC       O14966:RAB29; NbExp=7; IntAct=EBI-5323863, EBI-372165;
CC       Q63481:Rab29 (xeno); NbExp=3; IntAct=EBI-5323863, EBI-6513837;
CC       Q13637:RAB32; NbExp=6; IntAct=EBI-5323863, EBI-9837586;
CC       P61020:RAB5B; NbExp=9; IntAct=EBI-5323863, EBI-399401;
CC       P61021:Rab5b (xeno); NbExp=2; IntAct=EBI-5323863, EBI-8320093;
CC       P61006:RAB8A; NbExp=6; IntAct=EBI-5323863, EBI-722293;
CC       P63000:RAC1; NbExp=5; IntAct=EBI-5323863, EBI-413628;
CC       P41220:RGS2; NbExp=6; IntAct=EBI-5323863, EBI-712388;
CC       P62906:RPL10A; NbExp=2; IntAct=EBI-5323863, EBI-356860;
CC       P26373:RPL13; NbExp=2; IntAct=EBI-5323863, EBI-356849;
CC       P50914:RPL14; NbExp=2; IntAct=EBI-5323863, EBI-356746;
CC       P62750:RPL23A; NbExp=2; IntAct=EBI-5323863, EBI-353254;
CC       P62280:RPS11; NbExp=3; IntAct=EBI-5323863, EBI-1047710;
CC       P62841:RPS15; NbExp=9; IntAct=EBI-5323863, EBI-372635;
CC       P62249:RPS16; NbExp=2; IntAct=EBI-5323863, EBI-352480;
CC       P15880:RPS2; NbExp=2; IntAct=EBI-5323863, EBI-443446;
CC       P60866:RPS20; NbExp=2; IntAct=EBI-5323863, EBI-353105;
CC       P62266:RPS23; NbExp=2; IntAct=EBI-5323863, EBI-353072;
CC       P42677:RPS27; NbExp=2; IntAct=EBI-5323863, EBI-356336;
CC       P23396:RPS3; NbExp=2; IntAct=EBI-5323863, EBI-351193;
CC       O15027:SEC16A; NbExp=6; IntAct=EBI-5323863, EBI-357515;
CC       Q99962:SH3GL2; NbExp=4; IntAct=EBI-5323863, EBI-77938;
CC       P12235:SLC25A4; NbExp=2; IntAct=EBI-5323863, EBI-359074;
CC       P05141:SLC25A5; NbExp=2; IntAct=EBI-5323863, EBI-355133;
CC       P12236:SLC25A6; NbExp=2; IntAct=EBI-5323863, EBI-356254;
CC       O95295:SNAPIN; NbExp=5; IntAct=EBI-5323863, EBI-296723;
CC       P37840:SNCA; NbExp=6; IntAct=EBI-5323863, EBI-985879;
CC       Q58A65:Spag9 (xeno); NbExp=2; IntAct=EBI-5323863, EBI-6530207;
CC       P07437:TUBB; NbExp=4; IntAct=EBI-5323863, EBI-350864;
CC       P04350:TUBB4A; NbExp=4; IntAct=EBI-5323863, EBI-355007;
CC       P31946:YWHAB; NbExp=5; IntAct=EBI-5323863, EBI-359815;
CC       P62258:YWHAE; NbExp=6; IntAct=EBI-5323863, EBI-356498;
CC       P61981:YWHAG; NbExp=4; IntAct=EBI-5323863, EBI-359832;
CC       P61983:Ywhag (xeno); NbExp=6; IntAct=EBI-5323863, EBI-359821;
CC       Q04917:YWHAH; NbExp=3; IntAct=EBI-5323863, EBI-306940;
CC       P27348:YWHAQ; NbExp=8; IntAct=EBI-5323863, EBI-359854;
CC       P63104:YWHAZ; NbExp=9; IntAct=EBI-5323863, EBI-347088;
CC   -!- SUBCELLULAR LOCATION: Membrane; Peripheral membrane protein.
CC       Cytoplasm. Perikaryon. Mitochondrion. Golgi apparatus. Cell
CC       projection, axon. Cell projection, dendrite. Endoplasmic reticulum
CC       {ECO:0000250}. Cytoplasmic vesicle, secretory vesicle, synaptic
CC       vesicle membrane {ECO:0000269|PubMed:24687852}; Peripheral
CC       membrane protein {ECO:0000269|PubMed:24687852}; Cytoplasmic side
CC       {ECO:0000269|PubMed:24687852}. Endosome {ECO:0000250}. Lysosome
CC       {ECO:0000250}. Mitochondrion outer membrane {ECO:0000250}.
CC       Mitochondrion inner membrane {ECO:0000250}. Mitochondrion matrix
CC       {ECO:0000250}. Note=Predominantly associated with intracytoplasmic
CC       vesicular and membranous structures (By similarity). Localized in
CC       the cytoplasm and associated with cellular membrane structures.
CC       Predominantly associated with the mitochondrial outer membrane of
CC       the mitochondria. Colocalized with RAB29 along tubular structures
CC       emerging from Golgi apparatus. Localizes in intracytoplasmic
CC       punctate structures of neuronal perikarya and dendritic and axonal
CC       processes. {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Expressed in the brain. Expressed in pyramidal
CC       neurons in all cortical laminae of the visual cortex, in neurons
CC       of the substantia nigra pars compacta and caudate putamen (at
CC       protein level). Expressed throughout the adult brain, but at a
CC       lower level than in heart and liver. Also expressed in placenta,
CC       lung, skeletal muscle, kidney and pancreas. In the brain,
CC       expressed in the cerebellum, cerebral cortex, medulla, spinal cord
CC       occipital pole, frontal lobe, temporal lobe and putamen.
CC       Expression is particularly high in brain dopaminoceptive areas.
CC       {ECO:0000269|PubMed:15541308, ECO:0000269|PubMed:15541309,
CC       ECO:0000269|PubMed:16532471, ECO:0000269|PubMed:17120249}.
CC   -!- DOMAIN: The seven-bladed WD repeat region is critical for synaptic
CC       vesicle trafficking and mediates interaction with multiple
CC       vesicle-associated presynaptic proteins.
CC       {ECO:0000269|PubMed:24687852}.
CC   -!- DOMAIN: The Roc domain mediates homodimerization and regulates
CC       kinase activity. {ECO:0000269|PubMed:18230735}.
CC   -!- PTM: Autophosphorylated.
CC   -!- DISEASE: Parkinson disease 8 (PARK8) [MIM:607060]: A slowly
CC       progressive neurodegenerative disorder characterized by
CC       bradykinesia, rigidity, resting tremor, postural instability,
CC       neuronal loss in the substantia nigra, and the presence of
CC       neurofibrillary MAPT (tau)-positive and Lewy bodies in some
CC       patients. {ECO:0000269|PubMed:15541308,
CC       ECO:0000269|PubMed:15541309, ECO:0000269|PubMed:15680455,
CC       ECO:0000269|PubMed:15680456, ECO:0000269|PubMed:15680457,
CC       ECO:0000269|PubMed:15726496, ECO:0000269|PubMed:15732108,
CC       ECO:0000269|PubMed:15811454, ECO:0000269|PubMed:15852371,
CC       ECO:0000269|PubMed:15880653, ECO:0000269|PubMed:15925109,
CC       ECO:0000269|PubMed:15929036, ECO:0000269|PubMed:16102999,
CC       ECO:0000269|PubMed:16157901, ECO:0000269|PubMed:16157908,
CC       ECO:0000269|PubMed:16157909, ECO:0000269|PubMed:16172858,
CC       ECO:0000269|PubMed:16240353, ECO:0000269|PubMed:16247070,
CC       ECO:0000269|PubMed:16250030, ECO:0000269|PubMed:16251215,
CC       ECO:0000269|PubMed:16269541, ECO:0000269|PubMed:16272164,
CC       ECO:0000269|PubMed:16272257, ECO:0000269|PubMed:16298482,
CC       ECO:0000269|PubMed:16321986, ECO:0000269|PubMed:16333314,
CC       ECO:0000269|PubMed:16533964, ECO:0000269|PubMed:17114044,
CC       ECO:0000269|PubMed:18213618, ECO:0000269|PubMed:21850687,
CC       ECO:0000269|PubMed:22956510, ECO:0000269|PubMed:23395371}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY792511; AAV63975.1; -; mRNA.
DR   EMBL; AC079630; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC084290; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC107023; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL834529; CAD39185.1; -; mRNA.
DR   CCDS; CCDS31774.1; -.
DR   RefSeq; NP_940980.3; NM_198578.3.
DR   UniGene; Hs.187636; -.
DR   PDB; 2ZEJ; X-ray; 2.00 A; A/B=1333-1516.
DR   PDB; 3D6T; X-ray; 2.43 A; B=1335-1505.
DR   PDB; 5MY9; X-ray; 1.33 A; P=929-941.
DR   PDB; 5MYC; X-ray; 1.46 A; P=904-941.
DR   PDBsum; 2ZEJ; -.
DR   PDBsum; 3D6T; -.
DR   PDBsum; 5MY9; -.
DR   PDBsum; 5MYC; -.
DR   ProteinModelPortal; Q5S007; -.
DR   SMR; Q5S007; -.
DR   BioGrid; 125700; 152.
DR   DIP; DIP-29684N; -.
DR   IntAct; Q5S007; 549.
DR   MINT; MINT-7997594; -.
DR   STRING; 9606.ENSP00000298910; -.
DR   BindingDB; Q5S007; -.
DR   ChEMBL; CHEMBL1075104; -.
DR   GuidetoPHARMACOLOGY; 2059; -.
DR   iPTMnet; Q5S007; -.
DR   PhosphoSitePlus; Q5S007; -.
DR   BioMuta; LRRK2; -.
DR   DMDM; 294862450; -.
DR   MaxQB; Q5S007; -.
DR   PaxDb; Q5S007; -.
DR   PeptideAtlas; Q5S007; -.
DR   PRIDE; Q5S007; -.
DR   Ensembl; ENST00000298910; ENSP00000298910; ENSG00000188906.
DR   GeneID; 120892; -.
DR   KEGG; hsa:120892; -.
DR   UCSC; uc001rmg.5; human.
DR   CTD; 120892; -.
DR   DisGeNET; 120892; -.
DR   GeneCards; LRRK2; -.
DR   GeneReviews; LRRK2; -.
DR   HGNC; HGNC:18618; LRRK2.
DR   HPA; CAB037160; -.
DR   HPA; HPA014293; -.
DR   MalaCards; LRRK2; -.
DR   MIM; 168600; phenotype.
DR   MIM; 607060; phenotype.
DR   MIM; 609007; gene.
DR   neXtProt; NX_Q5S007; -.
DR   OpenTargets; ENSG00000188906; -.
DR   Orphanet; 2828; Young adult-onset Parkinsonism.
DR   PharmGKB; PA134968052; -.
DR   eggNOG; ENOG410IRBK; Eukaryota.
DR   eggNOG; KOG0192; Eukaryota.
DR   eggNOG; COG1100; LUCA.
DR   eggNOG; COG4886; LUCA.
DR   GeneTree; ENSGT00530000063477; -.
DR   HOGENOM; HOG000293315; -.
DR   HOVERGEN; HBG081937; -.
DR   InParanoid; Q5S007; -.
DR   KO; K08844; -.
DR   OMA; FKIRDQP; -.
DR   OrthoDB; EOG091G003N; -.
DR   PhylomeDB; Q5S007; -.
DR   TreeFam; TF313679; -.
DR   Reactome; R-HSA-8857538; PTK6 promotes HIF1A stabilization.
DR   SignaLink; Q5S007; -.
DR   SIGNOR; Q5S007; -.
DR   ChiTaRS; LRRK2; human.
DR   EvolutionaryTrace; Q5S007; -.
DR   GeneWiki; LRRK2; -.
DR   GenomeRNAi; 120892; -.
DR   PRO; PR:Q5S007; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000188906; -.
DR   CleanEx; HS_LRRK2; -.
DR   ExpressionAtlas; Q5S007; baseline and differential.
DR   Genevisible; Q5S007; HS.
DR   GO; GO:0044753; C:amphisome; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0044754; C:autolysosome; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0030424; C:axon; IDA:UniProtKB.
DR   GO; GO:0099400; C:caveola neck; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0032473; C:cytoplasmic side of mitochondrial outer membrane; IDA:UniProtKB.
DR   GO; GO:0031410; C:cytoplasmic vesicle; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0030425; C:dendrite; IDA:UniProtKB.
DR   GO; GO:0032839; C:dendrite cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005768; C:endosome; ISS:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005798; C:Golgi-associated vesicle; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0030426; C:growth cone; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0016234; C:inclusion body; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0005622; C:intracellular; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0030529; C:intracellular ribonucleoprotein complex; IEA:Ensembl.
DR   GO; GO:0005764; C:lysosome; ISS:UniProtKB.
DR   GO; GO:0005902; C:microvillus; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005743; C:mitochondrial inner membrane; ISS:UniProtKB.
DR   GO; GO:0005759; C:mitochondrial matrix; ISS:UniProtKB.
DR   GO; GO:0031966; C:mitochondrial membrane; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005741; C:mitochondrial outer membrane; ISS:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0097487; C:multivesicular body, internal vesicle; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0043005; C:neuron projection; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0043025; C:neuronal cell body; IDA:BHF-UCL.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0043204; C:perikaryon; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0098794; C:postsynapse; IEA:GOC.
DR   GO; GO:0030672; C:synaptic vesicle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0043195; C:terminal bouton; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0005802; C:trans-Golgi network; IEA:Ensembl.
DR   GO; GO:1990909; C:Wnt signalosome; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0003779; F:actin binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:1904713; F:beta-catenin destruction complex binding; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0030276; F:clathrin binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0039706; F:co-receptor binding; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0001948; F:glycoprotein binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0005525; F:GTP binding; IDA:UniProtKB.
DR   GO; GO:0034211; F:GTP-dependent protein kinase activity; IDA:BHF-UCL.
DR   GO; GO:0005096; F:GTPase activator activity; IDA:UniProtKB.
DR   GO; GO:0003924; F:GTPase activity; IDA:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0044325; F:ion channel binding; IPI:UniProtKB.
DR   GO; GO:0016301; F:kinase activity; IDA:UniProtKB.
DR   GO; GO:0004708; F:MAP kinase kinase activity; IDA:BHF-UCL.
DR   GO; GO:0008017; F:microtubule binding; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0036479; F:peroxidase inhibitor activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0051018; F:protein kinase A binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0030159; F:receptor signaling complex scaffold activity; IC:ParkinsonsUK-UCL.
DR   GO; GO:0017048; F:Rho GTPase binding; IPI:BHF-UCL.
DR   GO; GO:0000149; F:SNARE binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0017075; F:syntaxin-1 binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0015631; F:tubulin binding; IDA:BHF-UCL.
DR   GO; GO:0000187; P:activation of MAPK activity; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0000186; P:activation of MAPKK activity; IDA:BHF-UCL.
DR   GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0019722; P:calcium-mediated signaling; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0034613; P:cellular protein localization; ISS:ParkinsonsUK-UCL.
DR   GO; GO:1903351; P:cellular response to dopamine; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0071287; P:cellular response to manganese ion; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0034599; P:cellular response to oxidative stress; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0009267; P:cellular response to starvation; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0008340; P:determination of adult lifespan; IMP:BHF-UCL.
DR   GO; GO:0006897; P:endocytosis; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0060079; P:excitatory postsynaptic potential; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0035640; P:exploration behavior; IMP:BHF-UCL.
DR   GO; GO:0007030; P:Golgi organization; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0046039; P:GTP metabolic process; IDA:BHF-UCL.
DR   GO; GO:0048312; P:intracellular distribution of mitochondria; IMP:BHF-UCL.
DR   GO; GO:0035556; P:intracellular signal transduction; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0035641; P:locomotory exploration behavior; IEA:Ensembl.
DR   GO; GO:0007040; P:lysosome organization; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0000165; P:MAPK cascade; IDA:UniProtKB.
DR   GO; GO:0051646; P:mitochondrion localization; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0007005; P:mitochondrion organization; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1902902; P:negative regulation of autophagosome assembly; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1902236; P:negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0090394; P:negative regulation of excitatory postsynaptic potential; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0034260; P:negative regulation of GTPase activity; IDA:MGI.
DR   GO; GO:1903206; P:negative regulation of hydrogen peroxide-induced cell death; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1902823; P:negative regulation of late endosome to lysosome transport; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0016242; P:negative regulation of macroautophagy; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1901215; P:negative regulation of neuron death; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0032091; P:negative regulation of protein binding; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0010955; P:negative regulation of protein processing; IDA:ParkinsonsUK-UCL.
DR   GO; GO:1903217; P:negative regulation of protein processing involved in protein targeting to mitochondrion; IC:ParkinsonsUK-UCL.
DR   GO; GO:1903215; P:negative regulation of protein targeting to mitochondrion; IDA:ParkinsonsUK-UCL.
DR   GO; GO:1903125; P:negative regulation of thioredoxin peroxidase activity by peptidyl-threonine phosphorylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0007528; P:neuromuscular junction development; IMP:BHF-UCL.
DR   GO; GO:0070997; P:neuron death; IMP:BHF-UCL.
DR   GO; GO:0048812; P:neuron projection morphogenesis; IMP:UniProtKB.
DR   GO; GO:0021772; P:olfactory bulb development; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0016310; P:phosphorylation; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0010508; P:positive regulation of autophagy; IMP:UniProtKB.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0060161; P:positive regulation of dopamine receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IC:ParkinsonsUK-UCL.
DR   GO; GO:0043068; P:positive regulation of programmed cell death; IDA:UniProtKB.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; ISS:BHF-UCL.
DR   GO; GO:1902499; P:positive regulation of protein autoubiquitination; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0032092; P:positive regulation of protein binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0070585; P:protein localization to mitochondrion; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0072593; P:reactive oxygen species metabolic process; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0010506; P:regulation of autophagy; IMP:ParkinsonsUK-UCL.
DR   GO; GO:2000172; P:regulation of branching morphogenesis of a nerve; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1905289; P:regulation of CAMKK-AMPK signaling cascade; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0060828; P:regulation of canonical Wnt signaling pathway; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0061001; P:regulation of dendritic spine morphogenesis; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0060159; P:regulation of dopamine receptor signaling pathway; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0035564; P:regulation of kidney size; ISS:BHF-UCL.
DR   GO; GO:0040012; P:regulation of locomotion; IMP:BHF-UCL.
DR   GO; GO:0035751; P:regulation of lysosomal lumen pH; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0042391; P:regulation of membrane potential; IMP:BHF-UCL.
DR   GO; GO:0051900; P:regulation of mitochondrial depolarization; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0090140; P:regulation of mitochondrial fission; TAS:ParkinsonsUK-UCL.
DR   GO; GO:1902692; P:regulation of neuroblast proliferation; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1901214; P:regulation of neuron death; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0014041; P:regulation of neuron maturation; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0010738; P:regulation of protein kinase A signaling; ISS:ParkinsonsUK-UCL.
DR   GO; GO:1905279; P:regulation of retrograde transport, endosome to Golgi; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0051966; P:regulation of synaptic transmission, glutamatergic; ISS:ParkinsonsUK-UCL.
DR   GO; GO:2000300; P:regulation of synaptic vesicle exocytosis; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1902803; P:regulation of synaptic vesicle transport; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0006979; P:response to oxidative stress; IMP:BHF-UCL.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; IEA:InterPro.
DR   GO; GO:0022028; P:tangential migration from the subventricular zone to the olfactory bulb; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1904887; P:Wnt signalosome assembly; IPI:ParkinsonsUK-UCL.
DR   Gene3D; 1.25.10.10; -; 2.
DR   Gene3D; 1.25.40.20; -; 1.
DR   Gene3D; 2.130.10.10; -; 1.
DR   Gene3D; 3.80.10.10; -; 3.
DR   InterPro; IPR020683; Ankyrin_rpt-contain_dom.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR032171; COR.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR025875; Leu-rich_rpt_4.
DR   InterPro; IPR003591; Leu-rich_rpt_typical-subtyp.
DR   InterPro; IPR013684; MIRO-like.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR020859; ROC_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR005225; Small_GTP-bd_dom.
DR   InterPro; IPR015943; WD40/YVTN_repeat-like_dom.
DR   InterPro; IPR017986; WD40_repeat_dom.
DR   Pfam; PF16095; COR; 1.
DR   Pfam; PF12799; LRR_4; 1.
DR   Pfam; PF13855; LRR_8; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF08477; Roc; 1.
DR   SMART; SM00369; LRR_TYP; 7.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF48371; SSF48371; 2.
DR   SUPFAM; SSF50978; SSF50978; 1.
DR   SUPFAM; SSF52058; SSF52058; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   TIGRFAMs; TIGR00231; small_GTP; 1.
DR   PROSITE; PS51450; LRR; 11.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS51424; ROC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Autophagy; Cell junction; Cell projection;
KW   Coiled coil; Complete proteome; Cytoplasm; Cytoplasmic vesicle;
KW   Differentiation; Disease mutation; Endoplasmic reticulum; Endosome;
KW   Golgi apparatus; GTP-binding; GTPase activation; Kinase;
KW   Leucine-rich repeat; Lysosome; Membrane; Mitochondrion;
KW   Mitochondrion inner membrane; Mitochondrion outer membrane;
KW   Neurodegeneration; Nucleotide-binding; Parkinson disease;
KW   Parkinsonism; Phosphoprotein; Polymorphism; Reference proteome;
KW   Repeat; Serine/threonine-protein kinase; Synapse; Transferase;
KW   WD repeat.
FT   CHAIN         1   2527       Leucine-rich repeat serine/threonine-
FT                                protein kinase 2.
FT                                /FTId=PRO_0000086238.
FT   REPEAT      983   1004       LRR 1.
FT   REPEAT     1012   1033       LRR 2.
FT   REPEAT     1036   1057       LRR 3.
FT   REPEAT     1059   1080       LRR 4.
FT   REPEAT     1084   1105       LRR 5.
FT   REPEAT     1108   1129       LRR 6.
FT   REPEAT     1130   1150       LRR 7.
FT   REPEAT     1174   1196       LRR 8.
FT   REPEAT     1197   1218       LRR 9.
FT   REPEAT     1221   1241       LRR 10.
FT   REPEAT     1246   1267       LRR 11.
FT   REPEAT     1269   1291       LRR 12.
FT   DOMAIN     1328   1511       Roc. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00758}.
FT   DOMAIN     1879   2138       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REPEAT     2139   2183       WD 1.
FT   REPEAT     2188   2228       WD 2.
FT   REPEAT     2233   2276       WD 3.
FT   REPEAT     2281   2327       WD 4.
FT   REPEAT     2333   2377       WD 5.
FT   REPEAT     2402   2438       WD 6.
FT   REPEAT     2443   2497       WD 7.
FT   NP_BIND    1341   1348       GTP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00758,
FT                                ECO:0000269|PubMed:18230735}.
FT   NP_BIND    1885   1893       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND    2098   2121       GTP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00758}.
FT   NP_BIND    2295   2298       GTP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00758}.
FT   COILED      319    348       {ECO:0000255}.
FT   COMPBIAS    728    731       Poly-Leu.
FT   ACT_SITE   1994   1994       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING    1906   1906       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     935    935       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q5S006}.
FT   VARIANT      50     50       R -> H (in dbSNP:rs2256408).
FT                                /FTId=VAR_024931.
FT   VARIANT     119    119       L -> P (in dbSNP:rs33995463).
FT                                {ECO:0000269|PubMed:16172858,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_024932.
FT   VARIANT     228    228       C -> S (in dbSNP:rs56108242).
FT                                {ECO:0000269|PubMed:18213618}.
FT                                /FTId=VAR_054740.
FT   VARIANT     419    419       A -> V (in dbSNP:rs34594498).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_033903.
FT   VARIANT     551    551       N -> K (in dbSNP:rs7308720).
FT                                {ECO:0000269|PubMed:16172858,
FT                                ECO:0000269|PubMed:16251215,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:22415848}.
FT                                /FTId=VAR_024933.
FT   VARIANT     712    712       M -> V (in PARK8; dbSNP:rs199566791).
FT                                {ECO:0000269|PubMed:18213618}.
FT                                /FTId=VAR_054741.
FT   VARIANT     716    716       A -> V (in dbSNP:rs281865043).
FT                                {ECO:0000269|PubMed:18213618}.
FT                                /FTId=VAR_054742.
FT   VARIANT     723    723       I -> V (in dbSNP:rs10878307).
FT                                {ECO:0000269|PubMed:16172858,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:22415848}.
FT                                /FTId=VAR_024934.
FT   VARIANT     755    755       P -> L (in dbSNP:rs34410987).
FT                                /FTId=VAR_033904.
FT   VARIANT     793    793       R -> M (in PARK8; unknown pathological
FT                                significance; dbSNP:rs35173587).
FT                                {ECO:0000269|PubMed:16157908,
FT                                ECO:0000269|PubMed:16172858,
FT                                ECO:0000269|PubMed:16251215}.
FT                                /FTId=VAR_024935.
FT   VARIANT     871    871       K -> E (in dbSNP:rs281865044).
FT                                {ECO:0000269|PubMed:18213618}.
FT                                /FTId=VAR_054743.
FT   VARIANT     930    930       Q -> R (in PARK8; unknown pathological
FT                                significance; dbSNP:rs281865045).
FT                                {ECO:0000269|PubMed:16251215}.
FT                                /FTId=VAR_024936.
FT   VARIANT     944    944       D -> Y (in dbSNP:rs17519916).
FT                                /FTId=VAR_024937.
FT   VARIANT    1067   1067       R -> Q (in PARK8; dbSNP:rs111341148).
FT                                {ECO:0000269|PubMed:16247070}.
FT                                /FTId=VAR_024938.
FT   VARIANT    1096   1096       S -> C (in PARK8; unknown pathological
FT                                significance; dbSNP:rs76535406).
FT                                /FTId=VAR_024939.
FT   VARIANT    1122   1122       I -> V (in PARK8; dbSNP:rs34805604).
FT                                {ECO:0000269|PubMed:15541309,
FT                                ECO:0000269|PubMed:16172858}.
FT                                /FTId=VAR_024940.
FT   VARIANT    1228   1228       S -> T (in PARK8; dbSNP:rs60185966).
FT                                {ECO:0000269|PubMed:16251215}.
FT                                /FTId=VAR_024941.
FT   VARIANT    1262   1262       P -> A (in dbSNP:rs4640000).
FT                                {ECO:0000269|PubMed:16172858}.
FT                                /FTId=VAR_024942.
FT   VARIANT    1359   1359       K -> I (found in a renal cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21248752}.
FT                                /FTId=VAR_064728.
FT   VARIANT    1371   1371       I -> V (in PARK8; unknown pathological
FT                                significance; dbSNP:rs17466213).
FT                                {ECO:0000269|PubMed:16157901,
FT                                ECO:0000269|PubMed:16333314}.
FT                                /FTId=VAR_024943.
FT   VARIANT    1375   1375       D -> E (in dbSNP:rs28365226).
FT                                /FTId=VAR_047022.
FT   VARIANT    1398   1398       R -> H (in dbSNP:rs7133914).
FT                                {ECO:0000269|PubMed:16157901,
FT                                ECO:0000269|PubMed:16172858,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:22415848}.
FT                                /FTId=VAR_024944.
FT   VARIANT    1441   1441       R -> C (in PARK; shows an increase in
FT                                activity in both autophosphorylation and
FT                                phosphorylation of a generic substrate;
FT                                dbSNP:rs33939927).
FT                                {ECO:0000269|PubMed:15541309,
FT                                ECO:0000269|PubMed:16157909,
FT                                ECO:0000269|PubMed:16172858,
FT                                ECO:0000269|PubMed:16269541,
FT                                ECO:0000269|PubMed:16333314,
FT                                ECO:0000269|PubMed:16533964}.
FT                                /FTId=VAR_024945.
FT   VARIANT    1441   1441       R -> G (in PARK8; shows a progressive
FT                                reduction in neurite length and
FT                                branching; dbSNP:rs33939927).
FT                                {ECO:0000269|PubMed:15541308,
FT                                ECO:0000269|PubMed:15925109,
FT                                ECO:0000269|PubMed:16172858,
FT                                ECO:0000269|PubMed:16533964,
FT                                ECO:0000269|PubMed:17114044}.
FT                                /FTId=VAR_024946.
FT   VARIANT    1441   1441       R -> H (in PARK8; pathogenicity has yet
FT                                to be confirmed; dbSNP:rs34995376).
FT                                {ECO:0000269|PubMed:16157909,
FT                                ECO:0000269|PubMed:16172858}.
FT                                /FTId=VAR_024947.
FT   VARIANT    1514   1514       R -> Q (in PARK8; pathogenicity has yet
FT                                to be confirmed; might have an effect on
FT                                protein structure; dbSNP:rs35507033).
FT                                {ECO:0000269|PubMed:16172858,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:22415848}.
FT                                /FTId=VAR_024948.
FT   VARIANT    1542   1542       P -> S (in PARK8; pathogenicity has yet
FT                                to be confirmed; might have an effect on
FT                                protein structure; dbSNP:rs33958906).
FT                                {ECO:0000269|PubMed:16172858,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:22415848}.
FT                                /FTId=VAR_024949.
FT   VARIANT    1550   1550       R -> Q (in an ovarian mucinous carcinoma
FT                                sample; somatic mutation;
FT                                dbSNP:rs200212150).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040678.
FT   VARIANT    1598   1598       V -> E (in PARK8; pathogenicity has yet
FT                                to be confirmed; might have an effect on
FT                                protein structure; dbSNP:rs721710).
FT                                {ECO:0000269|PubMed:16172858}.
FT                                /FTId=VAR_024950.
FT   VARIANT    1628   1628       R -> P (may be associated with Parkinson
FT                                disease in some populations;
FT                                dbSNP:rs33949390).
FT                                {ECO:0000269|PubMed:16172858,
FT                                ECO:0000269|PubMed:21641266,
FT                                ECO:0000269|PubMed:22415848}.
FT                                /FTId=VAR_024951.
FT   VARIANT    1646   1646       M -> T (in dbSNP:rs35303786).
FT                                {ECO:0000269|PubMed:16172858,
FT                                ECO:0000269|PubMed:22415848}.
FT                                /FTId=VAR_024952.
FT   VARIANT    1647   1647       S -> T (in dbSNP:rs11564148).
FT                                {ECO:0000269|PubMed:16172858,
FT                                ECO:0000269|PubMed:22415848}.
FT                                /FTId=VAR_024953.
FT   VARIANT    1699   1699       Y -> C (in PARK8; shows no progressive
FT                                reduction in neurite length and
FT                                branching; dbSNP:rs35801418).
FT                                {ECO:0000269|PubMed:15541308,
FT                                ECO:0000269|PubMed:15541309,
FT                                ECO:0000269|PubMed:16172858,
FT                                ECO:0000269|PubMed:16272164,
FT                                ECO:0000269|PubMed:17114044}.
FT                                /FTId=VAR_024954.
FT   VARIANT    1723   1723       R -> P (in an ovarian serous carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040679.
FT   VARIANT    1728   1728       R -> H (in PARK8; dbSNP:rs145364431).
FT                                {ECO:0000269|PubMed:18213618}.
FT                                /FTId=VAR_054744.
FT   VARIANT    1728   1728       R -> L (in PARK8; dbSNP:rs145364431).
FT                                {ECO:0000269|PubMed:18213618}.
FT                                /FTId=VAR_054745.
FT   VARIANT    1869   1869       M -> T (in PARK8; pathogenicity has yet
FT                                to be confirmed; dbSNP:rs35602796).
FT                                {ECO:0000269|PubMed:16157908,
FT                                ECO:0000269|PubMed:16172858}.
FT                                /FTId=VAR_024955.
FT   VARIANT    1870   1870       L -> F (in dbSNP:rs281865053).
FT                                {ECO:0000269|PubMed:18213618}.
FT                                /FTId=VAR_054746.
FT   VARIANT    1906   1906       K -> M (does not inhibit interaction with
FT                                RAB29; shows a progressive increase in
FT                                neurite length and branching).
FT                                {ECO:0000269|PubMed:17114044,
FT                                ECO:0000269|PubMed:23395371}.
FT                                /FTId=VAR_071101.
FT   VARIANT    1941   1941       R -> H (in PARK8; dbSNP:rs77428810).
FT                                {ECO:0000269|PubMed:16272164}.
FT                                /FTId=VAR_024956.
FT   VARIANT    2012   2012       I -> T (in PARK8; pathogenicity
FT                                uncertain; dbSNP:rs34015634).
FT                                {ECO:0000269|PubMed:16172858}.
FT                                /FTId=VAR_024957.
FT   VARIANT    2019   2019       G -> S (in PARK8; shows an increase in
FT                                activity in both autophosphorylation and
FT                                phosphorylation of a generic substrate;
FT                                results in increased PRDX3
FT                                phosphorylation promoting dysregulation
FT                                of mitochondrial function and oxidative
FT                                damage; does not inhibit interaction with
FT                                RAB29; shows a progressive reduction in
FT                                neurite length and branching; shows
FT                                distinctive spheroid-like inclusions
FT                                within both neuronal processes and at
FT                                intracellular membranous structures;
FT                                shows lysosomal swelling and reduced
FT                                retrograde transport of selective cargo
FT                                between lysosomes and the Golgi
FT                                apparatus; shows apoptotic mechanism of
FT                                cell death; dbSNP:rs34637584).
FT                                {ECO:0000269|PubMed:15680455,
FT                                ECO:0000269|PubMed:15680456,
FT                                ECO:0000269|PubMed:15680457,
FT                                ECO:0000269|PubMed:15726496,
FT                                ECO:0000269|PubMed:15732108,
FT                                ECO:0000269|PubMed:15811454,
FT                                ECO:0000269|PubMed:15852371,
FT                                ECO:0000269|PubMed:15929036,
FT                                ECO:0000269|PubMed:16001413,
FT                                ECO:0000269|PubMed:16102999,
FT                                ECO:0000269|PubMed:16157901,
FT                                ECO:0000269|PubMed:16157908,
FT                                ECO:0000269|PubMed:16157909,
FT                                ECO:0000269|PubMed:16172858,
FT                                ECO:0000269|PubMed:16240353,
FT                                ECO:0000269|PubMed:16250030,
FT                                ECO:0000269|PubMed:16251215,
FT                                ECO:0000269|PubMed:16269541,
FT                                ECO:0000269|PubMed:16272164,
FT                                ECO:0000269|PubMed:16272257,
FT                                ECO:0000269|PubMed:16298482,
FT                                ECO:0000269|PubMed:16333314,
FT                                ECO:0000269|PubMed:16533964,
FT                                ECO:0000269|PubMed:17114044,
FT                                ECO:0000269|PubMed:18213618,
FT                                ECO:0000269|PubMed:21850687,
FT                                ECO:0000269|PubMed:22956510,
FT                                ECO:0000269|PubMed:23395371}.
FT                                /FTId=VAR_024958.
FT   VARIANT    2020   2020       I -> T (in PARK8; significant increase in
FT                                autophosphorylation of about 40% in
FT                                comparison to wild-type protein in vitro;
FT                                shows a progressive reduction in neurite
FT                                length and branching; dbSNP:rs35870237).
FT                                {ECO:0000269|PubMed:15541309,
FT                                ECO:0000269|PubMed:15880653,
FT                                ECO:0000269|PubMed:16172858,
FT                                ECO:0000269|PubMed:16251215,
FT                                ECO:0000269|PubMed:16321986,
FT                                ECO:0000269|PubMed:17114044}.
FT                                /FTId=VAR_024959.
FT   VARIANT    2081   2081       N -> D (in dbSNP:rs33995883).
FT                                {ECO:0000269|PubMed:16172858,
FT                                ECO:0000269|PubMed:22415848}.
FT                                /FTId=VAR_024960.
FT   VARIANT    2119   2119       P -> L (in dbSNP:rs12423862).
FT                                {ECO:0000269|PubMed:16172858}.
FT                                /FTId=VAR_024961.
FT   VARIANT    2141   2141       T -> M (in PARK8; dbSNP:rs111691891).
FT                                {ECO:0000269|PubMed:18213618}.
FT                                /FTId=VAR_054747.
FT   VARIANT    2143   2143       R -> H (in PARK8; dbSNP:rs201271001).
FT                                {ECO:0000269|PubMed:18213618}.
FT                                /FTId=VAR_054748.
FT   VARIANT    2261   2261       N -> I (in dbSNP:rs12581902).
FT                                {ECO:0000269|PubMed:16172858}.
FT                                /FTId=VAR_024962.
FT   VARIANT    2356   2356       T -> I (in PARK8; dbSNP:rs113511708).
FT                                {ECO:0000269|PubMed:16272164}.
FT                                /FTId=VAR_024963.
FT   VARIANT    2385   2385       G -> R (associated with Parkinson
FT                                disease; under conditions of oxidative
FT                                stress the variant protein is more toxic
FT                                and is associated with a higher rate of
FT                                apoptosis; reduced binding to synaptic
FT                                vesicles; dbSNP:rs34778348).
FT                                {ECO:0000269|PubMed:16172858,
FT                                ECO:0000269|PubMed:17019612,
FT                                ECO:0000269|PubMed:24687852}.
FT                                /FTId=VAR_024964.
FT   VARIANT    2395   2395       E -> K (in dbSNP:rs78964014).
FT                                {ECO:0000269|PubMed:18213618}.
FT                                /FTId=VAR_054749.
FT   VARIANT    2397   2397       M -> T (in dbSNP:rs3761863).
FT                                {ECO:0000269|PubMed:16157901,
FT                                ECO:0000269|PubMed:16172858,
FT                                ECO:0000269|PubMed:22415848}.
FT                                /FTId=VAR_024965.
FT   VARIANT    2466   2466       L -> H (in PARK8; dbSNP:rs281865057).
FT                                {ECO:0000269|PubMed:18213618}.
FT                                /FTId=VAR_054750.
FT   MUTAGEN    1343   1343       T->G: Decreased kinase activity; when
FT                                associated with Q-1398.
FT                                {ECO:0000269|PubMed:18230735}.
FT   MUTAGEN    1398   1398       R->Q: Decreased kinase activity; when
FT                                associated with G-1343.
FT                                {ECO:0000269|PubMed:18230735}.
FT   CONFLICT    212    212       L -> S (in Ref. 1; AAV63975).
FT                                {ECO:0000305}.
FT   HELIX       913    917       {ECO:0000244|PDB:5MYC}.
FT   STRAND     1336   1341       {ECO:0000244|PDB:2ZEJ}.
FT   HELIX      1347   1354       {ECO:0000244|PDB:2ZEJ}.
FT   STRAND     1370   1377       {ECO:0000244|PDB:2ZEJ}.
FT   STRAND     1389   1395       {ECO:0000244|PDB:2ZEJ}.
FT   HELIX      1398   1402       {ECO:0000244|PDB:2ZEJ}.
FT   HELIX      1406   1411       {ECO:0000244|PDB:2ZEJ}.
FT   STRAND     1412   1420       {ECO:0000244|PDB:2ZEJ}.
FT   HELIX      1421   1423       {ECO:0000244|PDB:2ZEJ}.
FT   HELIX      1425   1429       {ECO:0000244|PDB:2ZEJ}.
FT   HELIX      1431   1441       {ECO:0000244|PDB:2ZEJ}.
FT   STRAND     1446   1452       {ECO:0000244|PDB:2ZEJ}.
FT   HELIX      1454   1456       {ECO:0000244|PDB:2ZEJ}.
FT   HELIX      1459   1472       {ECO:0000244|PDB:2ZEJ}.
FT   TURN       1473   1475       {ECO:0000244|PDB:2ZEJ}.
FT   STRAND     1481   1487       {ECO:0000244|PDB:2ZEJ}.
FT   HELIX      1495   1509       {ECO:0000244|PDB:2ZEJ}.
SQ   SEQUENCE   2527 AA;  286103 MW;  26142A0CECBBC3F4 CRC64;
     MASGSCQGCE EDEETLKKLI VRLNNVQEGK QIETLVQILE DLLVFTYSER ASKLFQGKNI
     HVPLLIVLDS YMRVASVQQV GWSLLCKLIE VCPGTMQSLM GPQDVGNDWE VLGVHQLILK
     MLTVHNASVN LSVIGLKTLD LLLTSGKITL LILDEESDIF MLIFDAMHSF PANDEVQKLG
     CKALHVLFER VSEEQLTEFV ENKDYMILLS ALTNFKDEEE IVLHVLHCLH SLAIPCNNVE
     VLMSGNVRCY NIVVEAMKAF PMSERIQEVS CCLLHRLTLG NFFNILVLNE VHEFVVKAVQ
     QYPENAALQI SALSCLALLT ETIFLNQDLE EKNENQENDD EGEEDKLFWL EACYKALTWH
     RKNKHVQEAA CWALNNLLMY QNSLHEKIGD EDGHFPAHRE VMLSMLMHSS SKEVFQASAN
     ALSTLLEQNV NFRKILLSKG IHLNVLELMQ KHIHSPEVAE SGCKMLNHLF EGSNTSLDIM
     AAVVPKILTV MKRHETSLPV QLEALRAILH FIVPGMPEES REDTEFHHKL NMVKKQCFKN
     DIHKLVLAAL NRFIGNPGIQ KCGLKVISSI VHFPDALEML SLEGAMDSVL HTLQMYPDDQ
     EIQCLGLSLI GYLITKKNVF IGTGHLLAKI LVSSLYRFKD VAEIQTKGFQ TILAILKLSA
     SFSKLLVHHS FDLVIFHQMS SNIMEQKDQQ FLNLCCKCFA KVAMDDYLKN VMLERACDQN
     NSIMVECLLL LGADANQAKE GSSLICQVCE KESSPKLVEL LLNSGSREQD VRKALTISIG
     KGDSQIISLL LRRLALDVAN NSICLGGFCI GKVEPSWLGP LFPDKTSNLR KQTNIASTLA
     RMVIRYQMKS AVEEGTASGS DGNFSEDVLS KFDEWTFIPD SSMDSVFAQS DDLDSEGSEG
     SFLVKKKSNS ISVGEFYRDA VLQRCSPNLQ RHSNSLGPIF DHEDLLKRKR KILSSDDSLR
     SSKLQSHMRH SDSISSLASE REYITSLDLS ANELRDIDAL SQKCCISVHL EHLEKLELHQ
     NALTSFPQQL CETLKSLTHL DLHSNKFTSF PSYLLKMSCI ANLDVSRNDI GPSVVLDPTV
     KCPTLKQFNL SYNQLSFVPE NLTDVVEKLE QLILEGNKIS GICSPLRLKE LKILNLSKNH
     ISSLSENFLE ACPKVESFSA RMNFLAAMPF LPPSMTILKL SQNKFSCIPE AILNLPHLRS
     LDMSSNDIQY LPGPAHWKSL NLRELLFSHN QISILDLSEK AYLWSRVEKL HLSHNKLKEI
     PPEIGCLENL TSLDVSYNLE LRSFPNEMGK LSKIWDLPLD ELHLNFDFKH IGCKAKDIIR
     FLQQRLKKAV PYNRMKLMIV GNTGSGKTTL LQQLMKTKKS DLGMQSATVG IDVKDWPIQI
     RDKRKRDLVL NVWDFAGREE FYSTHPHFMT QRALYLAVYD LSKGQAEVDA MKPWLFNIKA
     RASSSPVILV GTHLDVSDEK QRKACMSKIT KELLNKRGFP AIRDYHFVNA TEESDALAKL
     RKTIINESLN FKIRDQLVVG QLIPDCYVEL EKIILSERKN VPIEFPVIDR KRLLQLVREN
     QLQLDENELP HAVHFLNESG VLLHFQDPAL QLSDLYFVEP KWLCKIMAQI LTVKVEGCPK
     HPKGIISRRD VEKFLSKKRK FPKNYMSQYF KLLEKFQIAL PIGEEYLLVP SSLSDHRPVI
     ELPHCENSEI IIRLYEMPYF PMGFWSRLIN RLLEISPYML SGRERALRPN RMYWRQGIYL
     NWSPEAYCLV GSEVLDNHPE SFLKITVPSC RKGCILLGQV VDHIDSLMEE WFPGLLEIDI
     CGEGETLLKK WALYSFNDGE EHQKILLDDL MKKAEEGDLL VNPDQPRLTI PISQIAPDLI
     LADLPRNIML NNDELEFEQA PEFLLGDGSF GSVYRAAYEG EEVAVKIFNK HTSLRLLRQE
     LVVLCHLHHP SLISLLAAGI RPRMLVMELA SKGSLDRLLQ QDKASLTRTL QHRIALHVAD
     GLRYLHSAMI IYRDLKPHNV LLFTLYPNAA IIAKIADYGI AQYCCRMGIK TSEGTPGFRA
     PEVARGNVIY NQQADVYSFG LLLYDILTTG GRIVEGLKFP NEFDELEIQG KLPDPVKEYG
     CAPWPMVEKL IKQCLKENPQ ERPTSAQVFD ILNSAELVCL TRRILLPKNV IVECMVATHH
     NSRNASIWLG CGHTDRGQLS FLDLNTEGYT SEEVADSRIL CLALVHLPVE KESWIVSGTQ
     SGTLLVINTE DGKKRHTLEK MTDSVTCLYC NSFSKQSKQK NFLLVGTADG KLAIFEDKTV
     KLKGAAPLKI LNIGNVSTPL MCLSESTNST ERNVMWGGCG TKIFSFSNDF TIQKLIETRT
     SQLFSYAAFS DSNIITVVVD TALYIAKQNS PVVEVWDKKT EKLCGLIDCV HFLREVMVKE
     NKESKHKMSY SGRVKTLCLQ KNTALWIGTG GGHILLLDLS TRRLIRVIYN FCNSVRVMMT
     AQLGSLKNVM LVLGYNRKNT EGTQKQKEIQ SCLTVWDINL PHEVQNLEKH IEVRKELAEK
     MRRTSVE
//
